|
The NIH Helping to End Addiction Long Term (HEAL) Initiative
|
Research Initiative
|
AHRQ, CDC, CMS, HRSA, OS, SAMHSA
|
NIDA, NCATS, NCCIH, NHLBI, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDDK, NIMH, NINDS, OD/OSP
|
In April 2018, the National Institutes of Health (NIH) launched the HEAL (Helping to End Addiction Long-termSM) Initiative, an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis. This Initiative will build on extensive, well-established NIH research, including basic science of the complex neurological pathways involved in pain and addiction, implementation science to develop and test treatment models, and research to integrate behavioral interventions with Medication-Assisted Treatment (MAT) for opioid use disorder (OUD) The NIH HEAL Initiative? will bolster research across NIH to improve treatments for opioid misuse and addiction and enhance pain management.
|
|
The President’s Roadmap to Empower Veterans and End a National Tragedy of Suicide (PREVENTS) Task Force
|
Committee, Work group, Advisory group, or Task Force
|
CDC, IHS, SAMHSA, AHRQ
|
NIMH, NINDS, OD/DPCPSI/OBSSR
|
The President's Roadmap to Empower Veterans and End a National Tragedy of Suicide (PREVENTS) will focus on a holistic public health approach to suicide prevention. PREVENTS seeks to change the culture surrounding mental health and suicide prevention through enhanced community integration, prioritized research activities, and implementation strategies that emphasize improved overall health and well-being.
|
|
The Scientific Registry of Transplant Recipients (SRTR) Visiting Committee
|
Committee, Work group, Advisory group, or Task Force
|
HRSA
|
NIAID
|
The SRTR Visiting Committee advises the SRTR on:(1) analytic methodologies to support the Organ Procurement and Transplantation Network policy development and evaluation; (2) objectives, study designs, and statistical methods for research projects performed by SRTR, including risk-adjusted analyses of organ procurement organization and transplant program performance; (3) methods used in simulated allocation models; (4) new areas of research and innovative advances in analytical methodologies that might improve the effectiveness of SRTR.
|
|
The United States Renal Data System (USRDS)
|
Resource Development
|
CMS, HRSA
|
NIDDK
|
The United States Renal Data System (USRDS) is a national data system that collects, analyzes, and distributes information about chronic kidney disease and end-stage renal disease (ESRD) in the United States. The missions of USRDS are: (1) To characterize the total renal patient population and describe the distribution of patients by socio-demographic variables across treatment modalities; (2) To report on the incidence, prevalence, mortality rates, and trends over time of renal disease by primary diagnosis, treatment modality and other variables; (3) To develop and analyze data on the effect of various modalities of treatment by disease and patient group categories; (4) To identify problems and opportunities for more focused special studies of renal research issues; (5) To conduct cost effectiveness studies and other economic studies of ESRD; and (6) To make the data available to investigators, and by supporting investigator-initiated projects, to conduct biomedical and economic analyses of ESRD patients.
|
|
The wireless sensing and artificial intelligence (AI) for smart healthcare Work Group
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NHLBI, NCI, NIBIB
|
The wireless sensing and AI for smart healthcare Working Group covers the topics related to wireless sensing and wireless in medical devices. Some of the topics include but not limited to: standards, interoperability, security, privacy, and safety.
|
|
Tissue Chip Testing Centers
|
Research Initiative
|
FDA
|
NCATS
|
The National Center for Advancing Translational Science (NCATS) funded Tissue Chip Testing Centers (TCTC) scientists have used a reference set of validation compounds vetted by pharmaceutical representatives through an NCATS partnership with the IQ Consortium and the Food and Drug Administration (FDA) to run tests to determine functionality, reproducibility, robustness, and reliability in these organ platforms. The TCTC scientists coordinated activities among Tissue Chip program-funded investigators and the FDA to support the progress of these chips, with the goal of getting chips to be used widely as a validated research tool and qualified for use in pre-clinical drug testing. The NextGen TCTCs funded in 2018 continued these goals, with a focus on building a self-sustaining financial business model for continuation of the TCTCs after the end of their funding periods.
|
|
Tobacco and Nicotine Research Interest Group (TANRIG)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, SAMHSA, FDA
|
ODP, FIC, NCI, NEI, NHGRI, NHLBI, NIAAA, NIAID, NICHD, NIDA, NIDCR, NIEHS, NIMHD, NIGMS, NLM, OD/DPCPSI
|
The Tobacco and Nicotine Research Interest Group (TANRIG) was formed in January 2003 with the goal of increasing collaboration, coordination, and communication of tobacco- and nicotine-related research among National Institutes of Health Institutes and Centers, as well as with other relevant US Department of Health and Human Services agencies.
|
|
Tobacco Centers of Regulatory Science (TCORS)
|
Research Initiative
|
FDA
|
ODP
|
The Tobacco Regulatory Science Program located in the National Institutes of Health (NIH) Office of Disease Prevention coordinates the trans-NIH collaboration effort with the Food and Drug Administration (FDA) Center for Tobacco Products to conduct research that is needed to ensure that US tobacco regulatory actions and activities are based on sound and relevant scientific evidence. The U54 Tobacco Centers of Regulatory Science (TCORS) are the centerpiece of this NIH-FDA collaboration. The TCORS are expected to demonstrate research excellence and leadership in tobacco regulatory science that will contribute to the science base that FDA will use to develop meaningful product regulation, which will, in turn, reduce the toll of tobacco-related disease, disability, and death in the United States. Essential elements of the TCORS include at least three theoretically grounded, strong research projects with an integrative theme; an Administrative Core and other cores as needed; the ability to conduct developmental/pilot and time-sensitive research; and a program for career development. Nine TCORS, made up of scientists with a broad range of expertise (e.g., epidemiology, economics, toxicology, addictions, and marketing) are currently funded.
|
|
Tobacco Product Disease Risks
|
Research Initiative
|
FDA
|
NCI
|
The National Cancer Institute (NCI) and the Food and Drug Administration (FDA) Center for Tobacco Products, in collaboration with the US Census Bureau, co-lead this study, which harmonizes data on cigarette, cigar, and pipe use from various Tobacco Use Supplements that have been administered over the years as part of the Current Population Survey. The participants in these surveys have been followed for mortality by linkage to the National Death Index. These data are used to provide contemporary estimates of the mortality risks of daily and non-daily use of cigarettes, pipes, and cigars.
|
|
Tobacco Regulatory Science Program (TRSP)
|
Research Initiative
|
FDA
|
ODP, CSR, NCI, NHLBI, NIAAA, NICHD, NIDA, NIEHS, OD/OER
|
Located in the National Institutes of Health (NIH) Office of Disease Prevention, the Tobacco Regulatory Science Program (TRSP) coordinates the trans-NIH collaborative effort with the US Food and Drug Administration’s (FDA) Center for Tobacco Products (CTP) to conduct research to support its regulatory activities over tobacco products. Within the framework of the Tobacco Control Act, the NIH and FDA formed an interagency partnership to foster tobacco regulatory research. The NIH has the infrastructure for the solicitation, review, and management of research. The FDA has expertise in tobacco regulatory science and the authority and resources to support research responsive to FDA’s regulatory authority. Support from FDA was used to fund grants and to provide administrative support and oversight to manage Funding Opportunity Announcements (FOA), application review, policy implementation and oversight, and communicating and reporting to a variety of sources.
|